Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers

Vaccine

Volumn 28, Issue 37, 2010, Pages 6076-6085

  Tribble, D ^a   Kaminski, R ^b   Cantrell, J ^a   Nelson, M ^c   Porter, C ^a   Baqar, S ^a   Williams, C ^a   Arora, R ^c   Saunders, J ^b   Ananthakrishnan, M ^b   Sanders, J ^c   Zaucha, G ^b   Turbyfill, R ^b   Oaks, E ^b  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Invaplex; Nasal vaccine; Shigella flexneri

Indexed keywords

IMMUNOGLOBULIN A; INVAPLEX 50 VACCINE; LIPOPOLYSACCHARIDE; SHIGELLA VACCINE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

ADULT; ANTIBODY PRODUCING CELL; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFERIOR TURBINATE EDEMA; MALE; NOSE CONGESTION; NOSE DISCHARGE; NOSE DISEASE; NOSE EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHINORRHEA; SHIGELLA FLEXNERI; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; DYSENTERY, BACILLARY; GUINEA PIG; IMMUNIZATION; IMMUNOGLOBULIN PRODUCING CELL; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MOUSE; MUCOSAL IMMUNITY; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADULT; ANIMALS; ANTIBODY FORMATION; ANTIBODY-PRODUCING CELLS; DYSENTERY, BACILLARY; FEMALE; GUINEA PIGS; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED BALB C; SHIGELLA FLEXNERI; SHIGELLA VACCINES; YOUNG ADULT;

EID: 77955509224     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.086     Document Type: Article

References (42)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999, 77(8):651-666.
2. Black R.E. Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis 1990, 12(January-February (Suppl. 1)):S73-S79.
3. Riddle M.S., Sanders J.W., Putnam S.D., Tribble D.R. Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): a systematic review. Am J Trop Med Hyg 2006, 74(May (5)):891-900.
4. Sharp T.W., Thornton S.A., Wallace M.R., Defraites R.F., Sanchez J.L., Batchelor R.A., et al. Diarrheal disease among military personnel during Operation Restore Hope, Somalia, 1992-1993. Am J Trop Med Hyg 1995, 52(February (2)):188-193.
5. Thornton S.A., Sherman S.S., Farkas T., Zhong W., Torres P., Jiang X. Gastroenteritis in US marines during operation Iraqi freedom. Clin Infect Dis 2005, 40(February (4)):519-525.
6. Pickering L.K. Antimicrobial resistance among enteric pathogens. Semin Pediatr Infect Dis 2004, 15(April (2)):71-77.
7. Jennison A.V., Verma N.K. Shigella flexneri infection: pathogenesis and vaccine development. FEMS Microbiol Rev 2004, 28(February (1)):43-58.
8. Sansonetti P.J., Tran Van Nhieu G., Egile C. Rupture of the intestinal epithelial barrier and mucosal invasion by Shigella flexneri. Clin Infect Dis 1999, 28(March (3)):466-475.
9. Schroeder G.N., Hilbi H. Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clinical Microbiol Rev 2008, 21(January (1)):134-156.
10. Li A., Rong Z.C., Ekwall E., Forsum U., Lindberg A.A. Serum antibody responses against shigella lipopolysaccharides and invasion plasmid-coded antigens in shigella infected Swedish patients. Scand J Infect Dis 1993, 25(5):569-577.
11. Oaks E.V., Hale T.L., Formal S.B. Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp. Infect Immun 1986, 53(July (1)):57-63.
12. Sandlin R.C., Goldberg M.B., Maurelli A.T. Effect of O side-chain length and composition on the virulence of Shigella flexneri 2a. Mol Microbiol 1996, 22(October (1)):63-73.
13. West N.P., Sansonetti P., Mounier J., Exley R.M., Parsot C., Guadagnini S., et al. Optimization of virulence functions through glucosylation of Shigella LPS. Science (New York, NY) 2005, 307(February (5713)):1313-1317.
14. Turbyfill K.R., Hartman A.B., Oaks E.V. Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine. Infect Immun 2000, 68(December (12)):6624-6632.
15. Oaks E.V., Turbyfill K.R. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine 2006, 24(March (13)):2290-2301.
16. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 2001, 51(September (1-3)):21-42.
17. Mills J.A., Buysse J.M., Oaks E.V. Shigella flexneri invasion plasmid antigens B and C: epitope location and characterization with monoclonal antibodies. Infect Immun 1988, 56(November (11)):2933-2941.
18. Turbyfill K.R., Kaminski R.W., Oaks E.V. Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a. Vaccine 2008, 26(March (10)):1353-1364.
19. Karkhanis Y.D., Zeltner J.Y., Jackson J.J., Carlo D.J. A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria. Anal Biochem 1978, 85(April (2)):595-601.
20. Gizurarson S., Georgsson G., Aggerbeck H., Thorarinsdottir H., Heron I. Evaluation of local toxicity after repeated intranasal vaccination of guinea-pigs. Toxicology 1996, 107(Jan (1)):61-68.
21. Bahnemann R.J.M., Karbe E., Kaufmann W., Morawietz G., Nolte T., Rittinghausen S. RITA-registry of industrial toxicology animal data-guides for organ sampling and trimming procedures in rats. Exp Toxic Pathol 1995, 47:247-266.
22. Mallett C.P., VanDeVerg L., Collins H.H., Hale T.L. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine 1993, 11:190-196.
23. Hartman A.B., Van de Verg L.L., Collins H.H., Tang D.B., Bendiuk N.O., Taylor D.N., et al. Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. Infect Immun 1994, 62(February (2)):412-420.
24. Hansel F. Observations on the cytology of the secretions in allergy of the nose and paranasal sinuses. J Allergy 1934, 5:357-366.
25. Jalowayski A. A practical guide for diagnostic nasal cytology 1991, Synbiotics Corp., San Diego, CA.
26. Gaspari M.M., Brennan P.T., Solomon S.M., Elson C.O. A method of obtaining, processing, and analyzing human intestinal secretions for antibody content. J immunol Methods 1988, 110(May (1)):85-91.
27. O'Mahony S., Barton J.R., Crichton S., Ferguson A. Appraisal of gut lavage in the study of intestinal humoral immunity. Gut 1990, 31(December (12)):1341-1344.
28. Ahren C., Andersson K., Wiklund G., Wenneras C., Svennerholm A.M. Optimization of the intestinal lavage procedure for determination of intestinal immune responses. Vaccine 1995, 13(December (18)):1754-1758.
29. Kaminski R.W., Turbyfill K.R., Oaks E.V. Mucosal adjuvant properties of the Shigella invasin complex. Infect Immun 2006, 74(May (5)):2856-2866.
30. Baqar S., Applebee L.A., Gilliland T.C., Lee L.H., Porter C.K., Guerry P. Immunogenicity and protective efficacy of recombinant Campylobacter jejuni flagellum-secreted proteins in mice. Infect Immun 2008, 76(July (7)):3170-3175.
31. Kaminski R.W., Turbyfill K.R., Chao C., Ching W.M., Oaks E.V. Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines. Clin Vaccine Immunol 2009, 16(April (4)):574-586.
32. Coster T.S., Hoge C.W., VanDeVerg L.L., Hartman A.B., Oaks E.V., Venkatesan M.M., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999, 67(July (7)):3437-3443.
33. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007, 5(July (7)):540-553.
34. Kaminski R.W., Oaks E.V. Inactivated and subunit vaccines to prevent shigellosis. Expert Rev Vaccines 2009, 8(December (12)):1693-1704.
35. Formal S.B., Oaks E.V., Olsen R.E., Wingfield-Eggleston M., Snoy P.J., Cogan J.P. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J Infect Dis 1991, 164(September (3)):533-537.
36. Ferreccio C., Prado V., Ojeda A., Cayyazo M., Abrego P., Guers L., et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol 1991, 134(September (6)):614-627.
37. DuPont H.L., Hornick R.B., Snyder M.J., Libonati J.P., Formal S.B., Gangarosa E.J. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis 1972, 125(January (1)):12-16.
38. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999, 282(July (2)):137-144.
39. Fries L.F., Montemarano A.D., Mallett C.P., Taylor D.N., Hale T.L., Lowell G.H. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immun 2001, 69(July (7)):4545-4553.
40. Slutter B., Hagenaars N., Jiskoot W. Rational design of nasal vaccines. J Drug Target 2008, 16(January (1)):1-17.
41. Venkatesan M.M., Ranallo R.T. Live-attenuated Shigella vaccines. Expert Rev Vaccines 2006, 5(October (5)):669-686.
42. Kotloff K.L., Nataro J.P., Losonsky G.A., Wasserman S.S., Hale T.L., Taylor D.N., et al. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 1995, 13(November (16)):1488-1494.